LUTEINIZING HORMONE TO FOLLICLE STIMULATING HORMONE RATIO IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME
AbstractBackground: Polycystic ovary syndrome is the most commonly occurring endocrinopathy in females of reproductive age group. It is characterized by a wide range of signs and symptoms resulting from hormonal derangements leading to reduced fertility. Methods: This was a cross-sectional (comparative) study. We took 40 cases of polycystic ovary syndrome and 40 controls of infertility without polycystic ovary syndrome depending on the presence of clinical features and ultrasound scans. Blood samples were collected and assayed for luteinizing hormone and follicle stimulating hormone. Data was analyzed with SPSS-19. Results: Luteinizing hormone to follicle stimulating hormone ratio was raised in 3 out of 35 patients (8%) in cases and in 2 out of 39 patients (5%) in controls. There was no statistically significant difference in the luteinizing hormone levels and the follicle stimulating hormone levels and the luteinizing hormone to follicle stimulating hormone ratio of the two groups as indicated by a p-value> 0.05. Conclusion: Luteinizing hormone to follicle stimulating hormone ratio was not found to be raised in majority of the polycystic ovary syndrome patients included in this study.Keywords: Polycystic Ovary Syndrome; Luteinizing Hormone; Follicle Stimulating Hormone; Infertility
Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev 2016;37(5):467–520.
Yao K, Bian C, Zhao X. Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy. Exp Ther Med 2017;14(2):1271–6.
Orisaka M, Hattori K, Fukuda S, Mizutani T, Miyamoto K, Sato T, et al. Dysregulation of Ovarian Follicular Development in Female Rat: LH Decreases FSH Sensitivity During Preantral-Early Antral Transition. Endocrinology 2013;154(8):2870–80.
Al-Jefout M, Alnawaiseh N, Al-Qtaitat A. Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. Sci Rep 2017;7(1):5339–48.
Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health 2015;12(7):1742–51.
Kaur R, Kaur T, Kaur A. Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. J Assist Reprod Genet 2018;35(6):1123–9.
Krouni A, Forouhari S, Namavarjahromi B, Dabbaghmanesh MH, Shayan A, Sepasi S, et al. The evaluation of the relationship between some related hormone levels and diet in obese or overweight patients with hirsutism: A randomized clinical trial. J Family Med Prim Care 2017;6(4):755–9.
Vander Borght M, Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem 2018;62:2–10.
Barber TM, Alvey C, Greenslade T, Gooding M, Barber D, Smith R, et al. Patterns of ovarian morphology in polycystic ovary syndrome: a study utilizing magnetic resonance imaging. Eur Radiol 2010;20(5):1207–13.
Beydoun HA, Beydoun MA, Wiggins N, Stadtmauer L. Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States. Maturitas 2012;71(1):55–61.
Dravecká I, Figurova J, Javorský M, Petrikova J, Valkova M, Lazurova I. The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome-a preliminary study. Physiol Res 2016;65(5):815–22.
Lewandowski KC, Cajdler-Luba A, Bieńkiewicz M, Lewiński A. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria. Neuro Endocrinol Lett 2011;32(6):847–56.
Ates S, Aydin S, Ozcan P, Soyman Z, Gokmen Karasu AF, Sevket O. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome. J Obstet Gynaecol 2018;38(2):236–40.
Goudas VT, Dumesic DA. Polycystic ovary syndrome. Endocrinol Metabol Clin N Am 1997;26(1):893–912.
Bothou A, Koutlaki N, Iatrakis G, Mastorakos G, Tsikouras P, Liberis V, et al. Antimüllerian hormone as indicator of ovarian dysfunction. Acta Endocrinol (Buchar) 2017;13(2):237–45.